Welcome to our dedicated page for Lineage Cell The news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell The stock.
Lineage Cell Therapeutics, Inc. develops allogeneic, or “off-the-shelf,” cell therapies for serious medical conditions using its AlloSCOPE cell differentiation and expansion platform. Its pipeline includes OpRegen, also known as RG6501, for geographic atrophy secondary to age-related macular degeneration; OPC1 for spinal cord injury; ReSonance, or ANP1, for hearing loss; and COR1 for corneal endothelial disease.
Recurring company news covers clinical data presentations, preclinical program launches, manufacturing and platform updates, research collaborations, milestone activity, financial results, business updates, and scientific governance. Updates frequently connect Lineage’s cell transplant programs with ophthalmology, neurology, auditory disease, and other non-oncology therapeutic areas.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotechnology company focused on developing allogeneic cell therapies for neurological conditions, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Lifesciences Conference.
The company's CEO, Brian M. Culley, is scheduled to present on February 11, 2025, at 12:40pm ET. The conference will be held virtually from February 11-12, 2025. Interested parties will be able to access a replay of the presentation through the Events and Presentations section of Lineage's website, with additional video content available on the company's Media page.
Lineage Cell Therapeutics (NYSE: LCTX) has completed the second tranche of its previously announced registered direct offering, receiving an additional $6 million in gross proceeds. This follows the first tranche closure in November 2024, which brought in $24 million. The total gross proceeds received now stand at $30 million.
The company could receive up to an additional $36 million upon full exercise of OpRegen® clinical milestone-linked warrants. The second tranche involved issuing 7,894,737 common shares with accompanying warrants to Broadwood Partners at $0.76 per share. The warrants are exercisable at $0.91 per share starting May 21, 2025, expiring on May 21, 2028, or 90 days after announcing intent to advance OpRegen into a phase 2 or 3 clinical trial.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotech firm developing allogeneic cell therapies, has published a letter to shareholders detailing recent achievements and its 2025 outlook. Lineage specializes in cell transplants, using mature, differentiated cells to replace lost or dysfunctional cells in conditions like dry age-related macular degeneration (dry-AMD). Their lead program, OpRegen, is in a Phase 2a trial in partnership with Roche and Genentech.
Lineage's financing strategy has secured $24 million in gross proceeds with an additional $6 million expected, extending their operational runway into Q1 2027. They have also issued warrants for up to $36 million, contingent on OpRegen’s advancement. The company aims to demonstrate scalable manufacturing capabilities, aspiring to produce thousands of doses from a single donor.
Looking ahead, Lineage plans to support OpRegen’s development while advancing its other programs, including OPC1 for spinal cord injuries and ReSonance™ for hearing loss. The company emphasizes its potential for long-term value creation through its unique cell transplant approach.
Lineage Cell Therapeutics (LCTX) announced the first closing of a registered direct offering of up to $66 million. The company issued 31,578,951 common shares and warrants at $0.76 per share to healthcare-focused institutional investors, receiving $24 million in gross proceeds. An additional $6 million is expected from Broadwood Partners pending shareholder approval. The warrants, exercisable at $0.91 per share, could provide up to $36 million in additional proceeds if fully exercised. The funds will be used for working capital, research and development, and capital expenditures.
Lineage Cell Therapeutics (NYSE: LCTX) has announced a registered direct offering of up to $66 million through the sale of 39,473,688 common shares and warrants. The offering includes $30 million upfront ($24 million from institutional investors and $6 million from Broadwood Partners) at $0.76 per share-warrant combination. Additional proceeds of up to $36 million may come from warrant exercises at $0.91 per share. The warrants are exercisable after six months and expire within three years or 90 days after OpRegen's Phase 2/3 trial announcement. The offering to institutional investors should close around November 21, 2024, while Broadwood's portion requires shareholder approval.
Lineage Cell Therapeutics (LCTX) reported Q3 2024 financial results with revenues of $3.8 million, up from $1.2 million in Q3 2023. The company posted a net loss of $3.0 million ($0.02 per share), improved from $7.1 million loss year-over-year. Operating expenses decreased to $7.6 million from $7.9 million. Cash position of $32.7 million is expected to fund operations into Q1 2026.
Key highlights include OpRegen receiving RMAT designation from FDA, continued collaboration with Roche/Genentech, and presentation of ReSonance preclinical results at the Inner Ear Biology Workshop.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX) has scheduled its third quarter 2024 financial results announcement and business update for November 14, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on the same day. Investors can join via phone at (800) 715-9871 or through the company's website. A replay will be available online for 30 days and by phone until November 21, 2024, using conference ID 2238934.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotechnology company focused on developing allogeneic cell therapies, has announced its participation in the Maxim Group 2024 Virtual Healthcare Summit. The company's CEO, Brian M. Culley, will be featured in a fireside chat hosted by Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group.
The fireside chat is scheduled for Tuesday, October 15, 2024, at 11:00 a.m. ET. It will be available for viewing by registered conference attendees. This event provides an opportunity for Lineage Cell Therapeutics to showcase its progress and discuss its innovative approach to addressing unmet medical needs through allogeneic cell therapies.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX) announced that CEO Brian M. Culley will present at the International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium. Culley will participate in a panel on "Clinical Trial Updates: PSC-Derived Therapies of the Eye" on October 2nd, 2024. The symposium, held from October 2-4, 2024, focuses on PSC-Derived Cell Therapies.
The presentation will feature OpRegen® (RG6501), a suspension of human allogeneic retinal pigment epithelial (RPE) cells being developed to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). OpRegen is currently in a Phase 2a clinical study and is being developed in collaboration with Roche and Genentech. The presentation will be available on Lineage's website after the panel.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX) presented preclinical results for ReSonance (ANP1), its auditory neuronal cell transplant for hearing loss treatment, at the 59th Annual Inner Ear Biology Workshop. Key highlights include:
1. ReSonance is manufactured using a proprietary in-house process at clinical scale.
2. The product showed relevant in-vitro functional activity and durable engraftment in multiple preclinical hearing loss models.
3. ReSonance is formulated as an immediate-use, thaw-and-inject product.
4. The company successfully advanced from concept to preclinical testing, generating new intellectual property.
Lineage CEO Brian Culley emphasized the company's manufacturing capabilities as a competitive advantage in the cell transplant space.